Polymorphisms in the ACE2 Locus Associate with Severity of COVID-19

Infection

Luke Wooster, BS^{1,2}*; Christopher J. Nicholson, PhD²*; Haakon H. Sigurslid, BS²; Christian L.

Lino Cardenas, PhD²; Rajeev Malhotra, MD^{2‡}

1. Case Western Reserve University School of Medicine, Cleveland, Ohio.

2. Cardiovascular Research Center, Division of Cardiology, Department of Medicine,

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

* Indicates co-first authors who contributed equally to the manuscript

[‡] Corresponding author:

Rajeev Malhotra, MD Massachusetts General Hospital Yawkey 5700; 55 Fruit Street Boston, MA 02114 Phone: 617-726-2677, Fax: 617-724-6767 Email: rmalhotra@mgh.harvard.edu

Abstract

Data from clinical studies suggests a strong association between underlying cardiometabolic disease and worse outcomes in COVID-19. Given that the SARS-CoV-2 virus has a unique marked affinity to the human angiotensin-converting enzyme 2 (ACE2) receptor, one potential explanation behind this phenomenon may involve the higher expression of ACE2 receptor in these patients. Here, we analyzed association between polymorphisms in the ACE2 locus and COVID-19 severity in 62 patients found to be COVID-19 positive by polymerase chain reaction. Of these patients, 23 required hospitalization due to COVID-19 infection. Of 61 *ACE2* single nucleotide polymorphisms (SNPs) genotyped in this patient cohort, 10 were significantly associated with tissue expression of ACE2. Logistic regression adjusted for age and for sex identified six of these ten SNPs to be significantly associated with hospitalization. These results provide preliminary evidence of a genetic link between the *ACE2* genotype and COVID-19 risk stratification and need for more intense therapy.

Introduction:

The mechanisms linked to severity of coronavirus disease 2019 (COVID-19), which has thus far taken the lives of more than 400,000 people worldwide, are not yet understood. Data from clinical studies suggests a strong association between underlying cardiometabolic disease and worse outcomes in COVID-19.¹ One potential explanation behind this phenomenon may involve the higher expression of angiotensin-converting enzyme 2 (ACE2) receptor in these patients.² COVID-19 infection is caused by binding of the SARS-CoV-2 virus through its spike (S) proteins to the ACE2 receptor, principally in Type II alveolar cells of the lung.³ ACE2 is also highly expressed in cardiac tissue and vascular endothelial cells, which may therefore provide a mechanism by which SARS-CoV-2 promotes direct injury of these tissues.^{4,5} Since interactions between the virus and ACE2 receptor are critical for virus entry into host cells, genetic polymorphisms that regulate ACE2 expression and/or the strength of these interactions may affect COVID-19 severity.⁶ Recent studies aimed to compare the prevalence of ACE2 functional coding variants in different populations with endemic COVID-19.6-8 However, to date there are no data showing a relationship between ACE2 genetic variants and clinical outcomes with COVID-19. The present study aims to analyze novel associations between mRNA expressionaltering genetic variants of human ACE2 and clinical severity in patients with COVID-19.

Methods and Findings:

Consecutive patients diagnosed with COVID-19 throughout the Partners Hospital System who were previously genotyped as part of the Partners Biobank repository were studied. All genotyping was performed using the Illumina Infinium MEGA Consortium v1 SNP array. The Genotype-Tissue Expression (GTEx) project dataset (v8 release) was used to determine SNPs

with a significant association with *ACE2* tissue mRNA expression (expression quantitative trait loci, eQTLs) with a minor allele frequency (MAF) of at least 5%.⁹ No coding variants were included in analysis as none met the threshold of 5% MAF in this cohort. *ACE2* is located on the X chromosome but has been shown to escape X inactivation.¹⁰ Therefore, logistic regression analysis adjusted for age and sex (Plink v1.07) was performed using allelic count where males were 0 or 1 and females 0, 1, or 2. We analyzed the effects of *ACE2* minor allele dosage on requirement for hospitalization due to COVID-19. This study was approved by the Partners institutional review board (IRB protocol #2020P000982).

Among 30,752 previously genotyped Caucasian patients in the Partners Biobank, 62 were found to be COVID-19 positive by polymerase chain reaction between 1st March and 16th May 2020. Hospitalization status was determined on 27th May by review of the electronic medical records. The median (IQR) age of this cohort was 62 (52, 73) years and 44% were female (**Table 1**). Of these patients, 23 (37%) required hospitalization due to COVID-19 infection. Across this cohort, we performed a case/control genetic association analysis on *ACE2* polymorphisms.⁹ Of 61 *ACE2* single nucleotide polymorphisms (SNPs) genotyped in this patient cohort, 10 were significant eQTLs for *ACE2* in at least one tissue type (*P*<1E-4) with some exhibiting linkage disequilibrium (**Table 2**). Of the 10 SNPs, five polymorphisms (rs4240157, rs6632680, rs4830965, rs1476524, and rs2048683), with minor alleles that associated with higher tissue expression of *ACE2*,⁹ were associated with increased need for hospitalization due to COVID-19 even after adjusting for age and sex (odds ratio 2.9-4.3, *P*<0.05 for all). Similarly, an *ACE2* polymorphism (rs1548474) whose minor allele associated with lower tissue expression was

associated with lesser COVID-19 severity not requiring hospitalization (odds ratio 0.27, 95% CI 0.08-0.85, P=0.025, Table 3).

Discussion:

Previous studies have investigated the potential for ACE2 polymorphisms to explain population-based differences in COVID-19 severity. Cao et al. found no direct evidence of population differences in coronavirus S-protein binding-resistant mutants. However, considerably higher allele frequencies for SNPs associated with higher ACE2 expression in tissues were observed in the East Asian populations.⁶ Asselta et al. reported no significant differences in the burden of rare deleterious ACE2 variants when comparing an Italian population with Europeans and East Asians.⁷ In contrast, using single cell sequencing, Zhao et al. demonstrated that ACE2 was more abundantly expressed in type II alveolar cells from an Asian male donor, when compared to white and African American donors.⁸ Whilst these studies shed light on the contribution of ACE2 genetic variation on population-based differences in coronavirus etiology, our analysis is the first to identify ACE2 polymorphisms that may influence disease severity. Importantly, genetic variants that have been associated with ACE2 mRNA expression levels associated with disease severity. Further studies that analyze the expression altering effects of these polymorphisms in lung and cardiovascular tissue will be informative to fully understand their role in COVID-19 infectivity and disease severity.

Conclusion:

In summary, in a cohort of patients with COVID-19 and pre-existing genotypic data, we found that six out of ten eQTL variants in *ACE2*, that are associated with altered *ACE2* tissue expression, were associated with the need for hospitalization due to COVID-19. These results,

although requiring replication in a validation cohort and in non-Caucasian populations, provide preliminary evidence of a genetic link between the *ACE2* genotype and COVID-19 disease severity and suggest that the *ACE2* genotype may inform COVID-19 risk stratification and need for more intense therapy.

Acknowledgements:

The authors have no conflicts of interest to disclose. Dr. Malhotra is supported by NHLBI R01 HL142809, American Heart Association grant 18TPA34230025, and the Wild Family Foundation.

Table 1. Demographic and clinical characteristics among Caucasian patients who did or

Characteristic		Required Hos		
	Total	No	Yes	P value
No.	62	39	23	
Age, median (IQR)	62 (52, 73)	61 (49, 68)	71 (59, 74)	0.061
Female, n (%)	27 (43.5)	18 (46.2)	9 (39.1)	0.609
Diabetes, n (%)	26 (41.9)	15 (38.5)	11 (47.8)	0.596
CVD, n (%)	21 (33.9)	11 (28.2)	10 (43.5)	0.271
Hyperlipidemia, n (%)	43 (69.4)	26 (66.7)	17 (73.9)	0.584
Hypertension*, n (%)	47 (75.8)	26 (66.7)	21 (91.3)	0.034
CKD, n (%)	10 (16.1)	7 (17.9)	3 (13.0)	0.731

did not require hospitalization due to COVID-19

CVD = cardiovascular disease; CKD = chronic kidney disease

For age, the Mann Whitney test was used. For the remaining categorical variables, Fisher's exact test was used.

* The presence of hypertension was not associated with any of the 10 SNPs in Table 2 by Fisher's exact test.

Table 2. Association of ACE2 eQTLs with ACE2 Tissue Expression.

SNP ID	NES	Top eQTL <i>P</i> value	Tissue
rs4240157 ⁺	0.37	1.80E-05	Brain - Substantia nigra
rs6632680	0.60	7.60E-16	Brain - Cortex Prostate Nerve – (Tibial) Artery – (Tibial)
rs1548474	-0.34	3.70E-05	Brain - Frontal Cortex
rs4830965 ⁺	0.35	1.80E-06	Brain - Caudate (basal ganglia) Nerve – (Tibial)
rs1476524 ⁺	0.33	6.30E-05	Brain - Anterior cingulate cortex
rs2048683	0.44	2.80E-07	Brain - Anterior cingulate cortex Nerve – (Tibial) Artery – (Tibial)
rs5936091∆	0.18	1.60E-05	Nerve - Tibial
rs112504565	-0.41	7.00E-05	Brain - Hypothalamus
rs705860 ∆	0.18	1.30E-05	Nerve - Tibial
rs1858558	-0.20	6.50E-05	Nerve - Tibial

+ and Δ : SNPs that demonstrated linkage disequilibrium with R² value ≥ 0.8 in a European cohort (<u>https://ldlink.nci.nih.gov/</u>).

SNP ID	Major Allele	Minor Allele	MAF in Hospitalized	MAF in Non- Hospitalized	Multivariable Logistic Regression OR*	OR 95% Confidence Interval	Multivariable Logistic Regression P value*
rs4240157 ⁺	С	Т	0.56	0.33	4.28	(1.34, 13.69)	0.014
rs6632680	Α	С	0.62	0.31	4.05	(1.32, 12.37)	0.014
rs1548474	G	Т	0.19	0.42	0.27	(0.08, 0.85)	0.025
rs4830965 ⁺	Α	G	0.50	0.28	3.45	(1.15, 10.29)	0.027
rs1476524+	Т	С	0.50	0.30	3.41	(1.12, 10.28)	0.030
rs2048683	Т	G	0.50	0.30	2.94	(1.02, 8.55)	0.047
rs5936091∆	G	А	0.28	0.17	1.63	(0.56, 4.73)	0.371
rs112504565	С	Т	0.14	0.17	0.85	(0.24, 2.95)	0.797
rs705860 ∆	Α	G	0.19	0.16	1.14	(0.37, 3.53)	0.819
rs1858558	Т	А	0.13	0.11	1.09	(0.26, 4.59)	0.910

Table 3. Association of ACE2 eQTLs with need for hospitalization in COVID-19 patients.

MAF = minor allele frequency; OR = odds ratio for requiring hospitalization; NES = Normalized effect size *adjusted for Age and Sex

+ and Δ : SNPs that demonstrated linkage disequilibrium with R² value ≥ 0.8 in a European cohort (<u>https://ldlink.nci.nih.gov/</u>).

References:

- 1. Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. *J Med Virol.* 2020.
- 2. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. *Eur J Clin Invest.* 2009;39(7):618-625.
- 3. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol.* 2020;5(4):562-569.
- 4. Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. *JAMA Cardiol.* 2020.
- 5. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020.
- 6. Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov.* 2020;6:11.
- 7. Rosanna Asselta EMP, Alberto Mantovani, Stefano Duga. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. *medRxiv*. 2020;2020.03.30.20047878.
- 8. Yu Zhao ZZ, Yujia Wang, Yueqing Zhou, Yu Ma, Wei Zuo. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. *bioRxiv*. 2020;2020.01.26.919985.
- 9. Consortium GT. The Genotype-Tissue Expression (GTEx) project. *Nat Genet*. 2013;45(6):580-585.
- 10. Tukiainen T, Villani AC, Yen A, et al. Landscape of X chromosome inactivation across human tissues. *Nature*. 2017;550(7675):244-248.